ArticleJournal of medicine and life2022
Barriers against the use of an optimal dose of metformin among patients with T2DM in Thi-Qar province, Iraq.
Article in Journal of medicine and life, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: a systematic review and meta-analysis with meta-regression of observational studies.BMC endocrine disorders · 2024Pooled it
- Metformin dose up-titration and glycemic control in type 2 diabetes in a resource-limited setting, northern Ethiopia: a retrospective cohort study.BMC endocrine disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is a disease with a high burden and prevalence and serious complications. Glycemic control is vital in delaying or preventing complications. Although many people do not take optimal doses, metformin is a cornerstone in managing type 2 diabetes mellitus (T2DM) in all guidelines. This study determined the barriers interfering with optimal metformin dosage. A cross-sectional study was conducted in Thi-Qar Specialized, Diabetes, Endocrine and Metabolism Center (TDEMC) at Thi-Qar, southern Iraq, from January 2019 to January 2020. 475 patients (274 females and 201 males) were included, and examination and lab investigations were performed. Only 22 (4.6%) patients took the optimal dose with no differences between gender. Of those who took metformin, 255 (74%) took it as a regular pill, 79 (23%) as a combined form with sulfonylureas (SUs), while only 10 (0.3%) took combined pills with Dipeptidyl Peptidase-4 inhibitors (DPP4i). 188 patients (65%) took metformin with meals, 84 (29%) before meals, and 19 (6%) after meals. Ignorance caused poor adherence to optimal dose in 165 patients (38.6%), neglect in 75 (17.6%), the cost in 5 (1.2%), 11 patients (2.6%) thought they did not need metformin, 37(8.7%) and 12 (2.8%) blame side effects and shortage of supply from public health care clinics (PHCC) as a cause, respectively. The rest of the patients had more than one cause. The most common side effects were abdominal pain and bloating, 5.9% and 3.8%, respectively. Other side effects were diarrhea in 0.2%, and 7.8% of patients developed more than one side effect. Ignorance and neglect were major obstacles, so educating doctors and patients and supplying the patient with optimal doses through PHCC may overcome the problem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.